ME03636B - Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola - Google Patents

Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola

Info

Publication number
ME03636B
ME03636B MEP-2020-39A MEP202039A ME03636B ME 03636 B ME03636 B ME 03636B ME P202039 A MEP202039 A ME P202039A ME 03636 B ME03636 B ME 03636B
Authority
ME
Montenegro
Prior art keywords
oxa
activity against
against pain
diazaspiro compounds
diazaspiro
Prior art date
Application number
MEP-2020-39A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marina Virgili-Bernado
Carmen Almansa-Rosales
Carlos Alegret-Molina
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of ME03636B publication Critical patent/ME03636B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2020-39A 2015-10-23 2016-10-21 Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola ME03636B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382523 2015-10-23
EP16784795.3A EP3365346B1 (en) 2015-10-23 2016-10-21 Oxa-diazaspiro compounds having activity against pain
PCT/EP2016/001742 WO2017067664A1 (en) 2015-10-23 2016-10-21 Oxa-diazaspiro compounds having activity against pain

Publications (1)

Publication Number Publication Date
ME03636B true ME03636B (me) 2020-07-20

Family

ID=54364221

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-39A ME03636B (me) 2015-10-23 2016-10-21 Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola

Country Status (30)

Country Link
US (1) US10689398B2 (me)
EP (1) EP3365346B1 (me)
JP (1) JP6884973B2 (me)
KR (1) KR20180073638A (me)
CN (1) CN108349998B (me)
AR (1) AR106448A1 (me)
AU (1) AU2016343551A1 (me)
BR (1) BR112018007269A2 (me)
CA (1) CA2999925A1 (me)
CO (1) CO2018004803A2 (me)
CY (1) CY1122708T1 (me)
DK (1) DK3365346T3 (me)
ES (1) ES2775522T3 (me)
HR (1) HRP20200309T1 (me)
HU (1) HUE047997T2 (me)
IL (1) IL258370A (me)
LT (1) LT3365346T (me)
MA (1) MA43158B1 (me)
ME (1) ME03636B (me)
MX (1) MX2018004777A (me)
PH (1) PH12018500682A1 (me)
PL (1) PL3365346T3 (me)
PT (1) PT3365346T (me)
RS (1) RS59956B1 (me)
RU (1) RU2018118399A (me)
SG (1) SG11201802988XA (me)
SI (1) SI3365346T1 (me)
TN (1) TN2018000091A1 (me)
TW (1) TW201731853A (me)
WO (1) WO2017067664A1 (me)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
PL3365346T3 (pl) 2015-10-23 2020-06-01 Esteve Pharmaceuticals, S.A. Związki oksa-diazaspiro o działaniu przeciwbólowym

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
WO1993013101A1 (en) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
EP1461339B1 (en) 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
WO2005046589A2 (en) * 2003-11-07 2005-05-26 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
WO2007124136A1 (en) 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Use of 4-amino-piperidines for treating sleep disorders
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
AU2008219980B2 (en) 2007-03-01 2012-01-12 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
ES2394547T3 (es) 2008-02-06 2013-02-01 Astrazeneca Ab Compuestos
EP2460347A4 (en) 2009-10-25 2014-03-12 Lg Electronics Inc METHOD FOR PROCESSING BROADCAST AND BROADCAST RECEIVER PROGRAM INFORMATION
CN103517910B (zh) * 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
WO2012125813A1 (en) 2011-03-16 2012-09-20 Access Business Group International Llc Humidifier with ultraviolet disinfection
EP2744333B1 (en) 2011-08-19 2016-10-05 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2017100951A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
EP3221315A1 (en) 2014-11-21 2017-09-27 Laboratorios Del. Dr. Esteve, S.A. 1,9-diazaspiro undecane compounds having multimodal activity against pain
PL3365346T3 (pl) 2015-10-23 2020-06-01 Esteve Pharmaceuticals, S.A. Związki oksa-diazaspiro o działaniu przeciwbólowym

Also Published As

Publication number Publication date
AU2016343551A1 (en) 2018-04-19
EP3365346B1 (en) 2019-12-04
PH12018500682A1 (en) 2018-10-01
WO2017067664A9 (en) 2017-06-29
BR112018007269A2 (pt) 2018-10-30
JP2018531263A (ja) 2018-10-25
CN108349998B (zh) 2021-10-29
DK3365346T3 (da) 2020-03-09
US20190002475A1 (en) 2019-01-03
CN108349998A (zh) 2018-07-31
HUE047997T2 (hu) 2020-05-28
RU2018118399A3 (me) 2020-01-31
PT3365346T (pt) 2020-03-05
RS59956B1 (sr) 2020-03-31
SI3365346T1 (sl) 2020-04-30
LT3365346T (lt) 2020-04-10
US10689398B2 (en) 2020-06-23
SG11201802988XA (en) 2018-05-30
MX2018004777A (es) 2018-06-19
EP3365346A1 (en) 2018-08-29
CY1122708T1 (el) 2021-03-12
CA2999925A1 (en) 2017-04-27
MA43158B1 (fr) 2020-03-31
TN2018000091A1 (en) 2019-07-08
CO2018004803A2 (es) 2018-07-19
ES2775522T3 (es) 2020-07-27
RU2018118399A (ru) 2019-11-25
AR106448A1 (es) 2018-01-17
PL3365346T3 (pl) 2020-06-01
TW201731853A (zh) 2017-09-16
JP6884973B2 (ja) 2021-06-09
HRP20200309T1 (hr) 2020-06-12
WO2017067664A1 (en) 2017-04-27
KR20180073638A (ko) 2018-07-02
IL258370A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
HK1250639A1 (zh) 抗微生物療法
HK1245266A1 (zh) 作為usp30抑制劑的1-氰基吡咯烷化合物
ZA201700670B (en) Compounds active towards bromodomains
HK1217083A1 (zh) 活動監視器
EP3245009C0 (en) ANTISEPTIC APPLICATOR
HUE043954T2 (hu) Szklerózis multiplex kezelése
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
GB2538043B (en) Activity monitor
GB201502412D0 (en) Therapeutic use
PT3359556T (pt) Modulação da atividade de citocinas gama-c
GB201508841D0 (en) Treatment
IL258370A (en) Oxa-diazaspiro compounds with analgesic activity
GB201604658D0 (en) Treatment for pain
HK1256692A1 (zh) 具有抗菌力的海綿
PT3365338T (pt) Derivados de morfolina substituídos tendo atividade contra a dor
GB201506786D0 (en) Therapeutic use
GB201503008D0 (en) Treatment
PT3365345T (pt) Composto de oxa- azaespiro tendo atividade contra a dor
GB201511410D0 (en) Pain supressars
GB2555225B (en) Hydrocarbon-contamination treatment unit
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment